Floatz logo

ONATASERTIB

Hormone Receptor-Positive Breast Cancer

CelgeneSmall moleculePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
89/ 100

Competitive context

117 Active assets in the Hormone Receptor-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

ONATASERTIB is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
45 / 100
View asset →
carcinoid tumorDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →